Imatinib
Imatinib 400 mg daily
400 mg · ITT
unresectable or metastatic KIT (CD117) positive GIST
median overall survival: 49 months, median follow up 37.5 months
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
GIST pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
6 arms have a reported figure in this set.
Imatinib 400 mg daily
400 mg · ITT
unresectable or metastatic KIT (CD117) positive GIST
median overall survival: 49 months, median follow up 37.5 months
Imatinib 800 mg daily
800 mg · ITT
unresectable or metastatic KIT (CD117) positive GIST
Comparator: imatinib 400 mg
median overall survival: 48.7 months, median follow up 37.5 months
Regorafenib 160 mg, 3 weeks on 1 off
160 mg · ITT
GIST after imatinib and sunitinib
Comparator: placebo
median overall survival: 17.4 months, final OS analysis, 162 events
GRID · NCT01271712
Placebo
placebo · ITT
GIST after imatinib and sunitinib
median overall survival: 17.4 months, final OS analysis; 88% crossed over
GRID · NCT01271712
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib, sunitinib and regorafenib
Comparator: placebo
median overall survival: 15.1 months, not tested for significance
INVICTUS · NCT03353753
Placebo
placebo · ITT
GIST after imatinib, sunitinib and regorafenib
median overall survival: 6.6 months, 66% switched to ripretinib
INVICTUS · NCT03353753
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.